Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. demonstrates a strong commitment to innovation through significant increases in research and development (R&D) investments, with expenses rising by 21% year-over-year to $14.0 million and projected to further increase by 36% in 2025 to $58.2 million. The company's strategic focus on partnerships with medical device firms is expected to foster commercialization of its promising product candidates, including BackBeat CNT and Virtue SAB, enhancing its market penetration potential. Additionally, while selling, general, and administrative (SG&A) expenses have increased by 12% to $26.9 million, the company continues to prioritize resources that could lead to long-term growth and scalability in the biomedical sector.

Bears say

Orchestra BioMed Holdings Inc. is classified as a development-stage company, having sustained operating losses since its inception, which raises concerns about its financial viability. There are indications that this trend of continual losses may persist, casting doubt on the company's ability to achieve and maintain consistent profitability in the future. These persistent financial challenges could detract from investor confidence and affect the company’s long-term sustainability and growth prospects.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.